Home Companies Remix Therapeutics COMPANY
Clinical Phase 2
5 open jobs · last seen Oct 23, 2026 · 3 sources
Keywords: small molecule Adenoid Cystic Carcinoma Metastatic Adenoid Cystic Carcinoma Recurrent Adenoid Cystic Carcinoma Myelodysplastic Syndromes Higher Risk Myelodysplastic Syndromes Acute Myeloid Leukemia Acute Myeloid Leukemia Refractory REM-422 Show all 9 keywords
Profile checked Oct 10, 2026
Hiring Title Location (from posting) Employer posted First seen Senior Director, GCP Quality Watertown, MA Oct 14, 2026 Oct 15, 2026 Associate Director, Clinical Data Management Watertown, MA Oct 2, 2026 Oct 9, 2026 Head of Medical Affairs Watertown, MA Sep 25, 2026 Oct 9, 2026 Vice President/Senior Director, Nonclinical Drug Safety & Toxicology Watertown, MA Sep 9, 2026 Oct 9, 2026 Vice President, Clinical Development Watertown, MA Jun 19, 2026 Oct 9, 2026
See all 5 jobs
At a glance HQ Watertown, MA source Stage Clinical Phase 2 Latest trial Phase 1: Study of REM-422 in Patients With AML or Higher Risk MDS (Apr 26, 2024) source Timeline Oct 9, 2026 Board tracked Radar started tracking this company’s job board (5 open jobs at last check). source ↗ Apr 26, 2024 Trial start Phase 1: Study of REM-422 in Patients With AML or Higher Risk MDS source ↗ Dec 20, 2023 Trial start Phase 1/Phase 2: Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma source ↗ Upcoming milestones Sep 30, 2027 (ESTIMATED) · Phase 1/Phase 2 · Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma · NCT06118086 Estimated primary completion per ClinicalTrials.gov. Dates move.
Open jobs 5 Title Location (from posting, not HQ) Employer posted First seen Level Senior Director, GCP Quality Watertown, MA Oct 14, 2026 Oct 15, 2026 Senior Description Associate Director, Clinical Data Management Watertown, MA Oct 2, 2026 Oct 9, 2026 Senior Description Head of Medical Affairs Watertown, MA Sep 25, 2026 Oct 9, 2026 Executive Description Vice President/Senior Director, Nonclinical Drug Safety & Toxicology Watertown, MA Sep 9, 2026 Oct 9, 2026 Executive Description Vice President, Clinical Development Watertown, MA Jun 19, 2026 Oct 9, 2026 Executive Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Clinical trials (lead sponsor) 2 Record Title Phase Status Start Primary completion NCT06118086 Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma Phase 1/Phase 2 Recruiting Dec 20, 2023 Sep 30, 2027 (estimated) NCT06297941 Study of REM-422 in Patients With AML or Higher Risk MDS Phase 1 Recruiting Apr 26, 2024 Mar 15, 2026 (estimated)
Raises and investors new Form D raises come from the company’s own SEC filing (last 2 years).
Investor Listed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗ Investor Listed in the portfolio of Atlas Venture (captured Oct 12, 2026). portfolio page ↗ Connect See your connections at Remix Therapeutics on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18
